4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Eloxx Pharmaceuticals, Inc. (ELOX) operates in the Biotechnology industry and is headquartered in Arlington, United States with about 10 employees. Its market capitalization is roughly $39 million. In the fiscal year ended 2025-12-31, ELOX reported $0M in revenue and ($6M) in net income.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $6M | $0M | $0M | — |
| Operating Income (EBIT) | ($6M) | ($2M) | ($17M) | ($34M) | — |
| Net Income | ($6M) | ($3M) | ($17M) | ($36M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($4M) | ($1M) |
| Net Income | ($4M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $5M | $3M | $2M | $21M | — |
| Total Liabilities | $17M | $27M | $24M | $32M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ELOX viewer.
About TickerBase · Data methodology & sources